“Our team set out to build a simple and complete solution for clinical researchers to analyze tumor DNA and produce actionable findings; with COMPASS they have achieved that aim.” said Wolfgang Daum, TOMA President and CEO.
FOSTER CITY, CA (PRWEB) March 30, 2017
American Association for Cancer Research (AACR) Annual Meeting 2017
TOMA Biosciences launches the COMPASS Tumor Profiling System™ - a simple and efficient workflow pathway from tumor, library preparation, sequencing, data analysis, clinical annotation, through reporting. Now, clinical researchers have everything they need to find clinically meaningful changes in tumor DNA.
The core of the COMPASS Tumor Profiling System is the Oligo Selective Sequencing capture assay, TOMA OS-Seq™, a patented technology invented at Stanford University. TOMA OS-Seq delivers unparalleled uniform sequence data of cancer genes from damaged DNA present in FFPE tumor specimens. The core offering of COMPASS allows the capture of tumor DNA from 130 cancer genes and can be customized to any genes of interest.
The COMPASS Tumor Profiling System includes:
- a comprehensive set of DNA library preparation reagents
- reference materials to assess sensitivity and specificity for validation
- proprietary sequence data analysis software for somatic variant identification
- options for annotation and reporting
COMPASS data analysis is performed through TOMA Stratus™. Stratus is a simple to use, cloud-based service with a web interface to easily upload data and download results. Within Stratus, COMPASS Analysis uses a proprietary method constructed to identify changes specific to the tumor DNA and removes inherited changes that many laboratories report without a specific somatic link.
COMPASS is a complete solution for clinical researchers looking to implement cancer genomics with superior performance while reducing cost and complexity.
“Our team set out to build a simple and complete solution for clinical researchers to analyze tumor DNA and produce actionable findings; with COMPASS they have achieved that aim.” said Wolfgang Daum, TOMA President and CEO.
“Finally, clinical researchers have what they need to simplify operations, improve accuracy and reduce costs. COMPASS can be implemented by clinical researchers and validation-ready in under a week.” commented Dr. Daum.
In addition to the core offering which includes the reagents, reference materials, and secondary analysis software, COMPASS enables several downstream interpretation options for clinical researchers, including access to curated clinical annotation information and reporting tools.
"FOR RESEARCH USE ONLY"
To learn more: attend ‘From Tumor to Action’ webinar.
About TOMA Biosciences
TOMA Biosciences Inc. is a genomics information company and the developer of the COMPASS Tumor Profiling System. COMPASS makes cancer genomics simple. The system includes everything a clinical laboratory needs to detect genomic changes in tumors including many missed by other methods. With its core sequencing technology invented at Stanford University, TOMA Biosciences provides a comprehensive solution to prepare tumor DNA for sequencing and reveal somatic variants. The company is led by innovative scientists, clinicians and technology developers to enable clinical laboratories, hospital systems and research institutions around the world to do cancer genomics. Headquartered in Foster City California, TOMA Biosciences is a commercial stage, private venture-backed company.